- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FIRST: Alkem Labs secures DCGI nod for launch of StemOne in India
StemOne has anti-inflammatory & immunosuppressive properties which reduce inflammation in the knee joint.
Mumbai: Alkem Laboratories has announced that the company has received approval from the Drug Controller General of India (DCGI) for the launch of StemOne in India. The product is indicated for the treatment of Knee Osteoarthritis. It is the first allogeneic cell therapy product to be approved for commercial use in India for Knee OA.The product has been developed by Stempeutics, a group...
Mumbai: Alkem Laboratories has announced that the company has received approval from the Drug Controller General of India (DCGI) for the launch of StemOne in India. The product is indicated for the treatment of Knee Osteoarthritis. It is the first allogeneic cell therapy product to be approved for commercial use in India for Knee OA.
India sees on an average 200,000 knee transplant surgeries each year, with an estimated cost burden of Rs 4000 crores
Read also: Alkem Labs secures CDSCO panel nod to conduct BE study of anti epileptic drug
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751